Isoniazid

Generic Name: Isoniazid

Brand Names: Isonarif, Isotamine, Isotamine B, Rifamate, Rifater

Drug Type: Small Molecule

Chemical Formula: C_₆H_₇N_₃O

CAS Number: 54-85-3

Unique Ingredient Identifier: V83O1VOZ8L

Background: Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Indication: Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.

Associated Conditions: Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis

Associated Therapies: -

Clinical Trials

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

Phase 2

Completed

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Rifampicin
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Linezolid
Drug: Clofazimine
Drug: Rifapentine
Drug: Levofloxacin
Drug: Bedaquiline

First Posted Date: 2018-03-22

Last Posted Date: 2023-08-14

Lead Sponsor: University College, London

Target Recruit Count: 675

Registration Number: NCT03474198

Locations: 🇮🇩
Saiful Anwar Hospital, Malang, Indonesia
🇺🇬
Joint Clinical Research Centre, Mbarara, Uganda
🇺🇬
Infectious Diseases Institute, Kampala, Uganda

and more 14 locations

Phase 2a Study of PBTZ169

Phase 2

Terminated

Conditions: Tuberculosis

Interventions: Drug: PBTZ169
Drug: Isoniazid

First Posted Date: 2017-11-07

Last Posted Date: 2020-03-09

Lead Sponsor: Nearmedic Plus LLC

Target Recruit Count: 16

Registration Number: NCT03334734

Treatment of Latent Tuberculosis in Socially Marginalised Citizens

Phase 4

Terminated

Conditions: Compliance, Patient

Interventions: Drug: Rifapentine
Drug: Isoniazid

First Posted Date: 2017-08-30

Last Posted Date: 2023-10-12

Lead Sponsor: Aarhus University Hospital

Target Recruit Count: 22

Registration Number: NCT03266991

Locations: 🇩🇰
Dept of Pulmonary Medicine, Esbjerg, Denmark

Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings

Not Applicable

Completed

Conditions: HIV/AIDS
Tuberculosis
Hepatitis
Addiction
Opioid Dependence

Interventions: Drug: Isoniazid
Drug: Methadone
Drug: Rifapentine

First Posted Date: 2017-03-24

Last Posted Date: 2024-10-04

Lead Sponsor: Yale University

Target Recruit Count: 1702

Registration Number: NCT03089983

Locations: 🇲🇾
Kajang Prison, Kajang, Selangor, Malaysia

Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals

Phase 3

Completed

Conditions: HIV
Tuberculosis

Interventions: Drug: rifapentine + isoniazid
Drug: Isoniazid

First Posted Date: 2016-12-02

Last Posted Date: 2019-10-30

Lead Sponsor: The Aurum Institute NPC

Target Recruit Count: 4027

Registration Number: NCT02980016

Locations: 🇿🇦
The Aurum Institute NPC, Johannesburg, Gauteng, South Africa

Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

Phase 4

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Levofloxacin

First Posted Date: 2016-09-15

Last Posted Date: 2017-03-20

Lead Sponsor: Beijing Chest Hospital

Target Recruit Count: 3900

Registration Number: NCT02901288

Locations: 🇨🇳
The Infectious Hospital of Hebi, Hebi, Henan, China
🇨🇳
Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China
🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China

and more 32 locations

The Correlate of Risk Targeted Intervention Study

Phase 2

Conditions: Tuberculosis

Interventions: Drug: Isoniazid
Drug: Rifapentine

First Posted Date: 2016-04-12

Last Posted Date: 2018-12-24

Lead Sponsor: University of Cape Town

Target Recruit Count: 2927

Registration Number: NCT02735590

Locations: 🇿🇦
Stellenbosch Immunology Research Group, Cape Town, Western Cape, South Africa
🇿🇦
Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban, KwaZulu-Natal, South Africa
🇿🇦
South African Tuberculosis Vaccine Initiative (SATVI), Worcester, Western Cape, South Africa

and more 1 locations

Infant TB Infection Prevention Study

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Drug: Isoniazid

First Posted Date: 2015-11-24

Last Posted Date: 2023-04-28

Lead Sponsor: University of Washington

Target Recruit Count: 300

Registration Number: NCT02613169

Locations: 🇰🇪
Kisumu County Hospital, Kisumu, Kenya

A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis

Phase 3

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Rifampicin
Drug: Isoniazid
Drug: Ethambutol
Drug: Pyrazinamide

First Posted Date: 2015-10-21

Last Posted Date: 2023-04-27

Lead Sponsor: St George's, University of London

Target Recruit Count: 672

Registration Number: NCT02581527

Locations: 🇺🇬
Epicentre, Mbarara, Uganda
🇵🇪
Hospital Nacional Dos de Mayo, Lima, Peru
🇳🇵
GENETUP, National Anti-TB Association, Kathmandu, Nepal

and more 3 locations

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Phase 3

Conditions: Tuberculosis

Interventions: Drug: Rifampin
Drug: Rifapentine
Drug: Isoniazid
Drug: Moxifloxacin
Drug: Pyrazinamide
Drug: Ethambutol
Dietary Supplement: Pyridoxine

First Posted Date: 2015-09-30

Last Posted Date: 2017-03-01

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 60

Registration Number: NCT02563327

Locations: 🇺🇬
Mulago Hospital, Kampala, Uganda

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy